Exposure–response of ciclosporin and methotrexate in children and young people with severe atopic dermatitis: a secondary analysis of the TREatment of severe Atopic dermatitis Trial (TREAT)
Clinical and Experimental Dermatology · 2025
DOI: 10.1093/ced/llaf147 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Mandy Wan und 29 weiteren Autor:innen. Beteiligte Einrichtung: Evelina Pharmacy, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Cyclosporine, Dermatitis, Atopic, Dermatologic Agents, Immunosuppressive Agents. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Medical Research Council, National Institute for Health Research (NIHR), Efficacy and Mechanism Evaluation (EME).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
This is a secondary analysis of a multicentre randomized controlled trial of ciclosporin and methotrexate in children and young people (CYP) with severe atopic dermatitis (AD). Longitudinal trough ciclosporin and erythrocyte methotrexate polyglutamate (MTX-PG) concentrations were measured to evaluate their associations with treatment response and adverse events. Both ciclosporin (4 mg kg–1 daily) and methotrexate (0.4 mg kg–1 weekly) led to a significant reduction in disease severity scores over the 36-week treatment period. Higher trough ciclosporin concentrations were associated with lower disease severity scores and may serve as a useful tool for therapeutic drug monitoring of ciclosporin in CYP with AD. However, in contrast to a previously published study, steady-state erythrocyte-MTX-PG concentrations showed no significant association with treatment response. Drug concentrations were comparable between patients with and without drug-related adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Evelina Pharmacy, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.
- Institute of Pharmaceutical Science, King's College London, London, UK.
- Department of Paediatric Dermatology, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, UK.
ORCID-Profile: Tess McPherson, Jane Ravenscroft, Bjorn R Thomas, Carsten Flohr
Förderung
- UK Medical Research Council
- National Institute for Health Research (NIHR)
- Efficacy and Mechanism Evaluation (EME)
Zitieren
APA
Wan, M., Jones, A. P., Maskrey, D., Arenas-Hernandez, M., Rosala-Hallas, A., Beattie, P. E., Baron, S., Browne, F., Brown, S. J., Gach, J. E., Greenblatt, D., Hearn, R., Hilger, E., Esdaile, B., Cork, M. J., Howard, E., Lovgren, M. L., August, S., Ashoor, F., …, & Flohr, C. (2025). Exposure–response of ciclosporin and methotrexate in children and young people with severe atopic dermatitis: a secondary analysis of the TREatment of severe Atopic dermatitis Trial (TREAT). Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llaf147
Vancouver
Wan M, Jones AP, Maskrey D, Arenas-Hernandez M, Rosala-Hallas A, Beattie PE, et al. Exposure–response of ciclosporin and methotrexate in children and young people with severe atopic dermatitis: a secondary analysis of the TREatment of severe Atopic dermatitis Trial (TREAT). Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llaf147
BibTeX
@article{Wan2025,
author = {Wan, Mandy and Jones, Ashley P and Maskrey, Daniel and Arenas-Hernandez, Monica and Rosala-Hallas, Anna and Beattie, Paula E and Baron, Susannah and Browne, Fiona and Brown, Sara J and Gach, Joanna E and Greenblatt, Danielle and Hearn, Ross and Hilger, Eva and Esdaile, Ben and Cork, Michael J and Howard, Emma and Lovgren, Marie-Louise and August, Suzannah and Ashoor, Farhiya and Williamson, Paula R and McPherson, Tess and O'Kane, Donal and Ravenscroft, Jane and Shaw, Lindsay and Sinha, Manish D and Spowart, Catherine and Thomas, Bjorn R and Sach, Tracey H and Irvine, Alan D and Flohr, Carsten},
title = {Exposure–response of ciclosporin and methotrexate in children and young people with severe atopic dermatitis: a secondary analysis of the TREatment of severe Atopic dermatitis Trial (TREAT)},
journal = {Clinical and Experimental Dermatology},
year = {2025},
doi = {10.1093/ced/llaf147}
}
EUVIMED